Granted Patent B2

US 8,129,405 · App. 13/011,131 · Granted Mar 6, 2012

Assignee: Almirall Prodesfarma S.A.

Abstract

Claims (15)

1. A pharmaceutical composition comprising:

(i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X − with a single negative charge is associated with the positive charge of the nitrogen atom; and

(ii) a β 2 agonist.

2. The composition of claim 1 further comprising a pharmaceutically acceptable carrier or diluent.

3. The composition of claim 1 wherein the anion X 31 is chloride, bromide, iodide, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p-toluenesulfonate, or trifluoroacetate.

4. The composition of claim 1 which is suitable for inhalation.

5. The composition of claim 1 wherein the composition is a liquid inhalant, powder inhalant, or inhalation aerosol.

6. The composition of claim 1 further comprising a steroid.

7. The composition of claim 6 further comprising a phosphodiesterase IV inhibitor.

8. The composition of claim 1 further comprising a phosphodiesterase IV inhibitor.

9. The composition of claim 2 wherein the pharmaceutically acceptable carrier or diluent is lactose.

10. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of the composition of claim 1 .

11. The method of claim 10 further comprising administering an effective amount of a steroid.

12. The method of claim 11 further comprising administering an effective amount of phosphodiesterase IV inhibitor.

13. The method of claim 10 further comprising administering an effective amount of phosphodiesterase IV inhibitor.

Assignments (5)

Priority Claims (1)

Continuity (9)